Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) has announced the results of a preclinical study of its lead compound, Telomir-1, conducted in an animal model of Werner Syndrome, a rare genetic disorder that causes premature aging. The study demonstrated that Telomir-1 effectively reset key biological aging markers, including DNA methylation, and restored healthy gene regulation. Notable findings included a significant increase in telomere length, a full reversal of muscle and body weight loss, up to a 50% reduction in oxidative stress markers, and 100% survival in treated animals compared to a 15% mortality rate in untreated controls. These results suggest that Telomir-1 may have potential as a therapeutic candidate for aging-related diseases. Telomir Pharmaceuticals plans to continue the development of Telomir-1, focusing on addressing mechanisms related to telomere dysfunction and epigenetic instability.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。